Bausch Health Cos (NYSE:BHC) Issues Earnings Results

Key Points

• Bausch Health Cos reported quarterly earnings of $0.90 per share, missing the consensus estimate of $0.97 by $0.07, despite achieving revenue of $2.57 billion compared to expected $2.47 billion.
• Insider trading activity shows Director John Paulson increased his stake by 12.19%, acquiring over 3.5 million shares valued at approximately $21.17 million.
• Analysts have mixed ratings on Bausch Health, with one evaluation lowering its stock from "buy" to "hold" and an average price target set at $7.38.

Bausch Health Cos (NYSE:BHC - Get Free Report) announced its earnings results on Wednesday. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.97 by ($0.07), Zacks reports. The company had revenue of $2.57 billion for the quarter, compared to analysts' expectations of $2.47 billion. Bausch Health Cos had a net margin of 0.99% and a negative return on equity of 852.36%. Bausch Health Cos updated its FY 2025 guidance to EPS.

Bausch Health Cos Stock Performance

Bausch Health Cos stock traded up $0.18 during mid-day trading on Tuesday, reaching $5.96. 1,826,796 shares of the company's stock were exchanged, compared to its average volume of 2,401,502. The business's fifty day simple moving average is $6.00 and its 200 day simple moving average is $6.07. The firm has a market capitalization of $2.21 billion, a PE ratio of 22.92 and a beta of 0.41. Bausch Health Cos has a one year low of $4.25 and a one year high of $9.85. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 141.90.

Insider Activity at Bausch Health Cos

In related news, Director John Paulson purchased 3,564,059 shares of the stock in a transaction that occurred on Friday, June 13th. The shares were bought at an average price of $5.94 per share, with a total value of $21,170,510.46. Following the acquisition, the director owned 32,791,702 shares of the company's stock, valued at $194,782,709.88. This trade represents a 12.19% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last quarter, insiders have purchased 6,352,667 shares of company stock valued at $35,870,767. Insiders own 8.12% of the company's stock.

Institutional Trading of Bausch Health Cos

Hedge funds have recently made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Bausch Health Cos by 3.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 324,847 shares of the company's stock valued at $2,102,000 after buying an additional 9,834 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Bausch Health Cos by 97.1% in the first quarter. Goldman Sachs Group Inc. now owns 948,322 shares of the company's stock valued at $6,136,000 after buying an additional 467,270 shares during the period. Jones Financial Companies Lllp raised its stake in shares of Bausch Health Cos by 1,548.9% in the first quarter. Jones Financial Companies Lllp now owns 24,965 shares of the company's stock valued at $162,000 after buying an additional 23,451 shares during the period. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Bausch Health Cos in the first quarter valued at $68,000. 78.65% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on BHC shares. Royal Bank Of Canada lifted their target price on Bausch Health Cos from $8.50 to $10.00 and gave the company a "sector perform" rating in a research report on Friday, May 2nd. Wall Street Zen raised Bausch Health Cos from a "hold" rating to a "buy" rating in a research report on Saturday.

About Bausch Health Cos

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.